Bicyclic ketone sulfonamide compounds
AssigneeAmgen Inc.
InventorsMatthew Weiss, Benjamin Charles Milgram, Thomas Dineen, John Stellwagen, Angel Guzman-Perez, Alessandro Boezio, Issac E. Marx
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of Formula (I), wherein: as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
Claims17
A compound of Formula (I), an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- Wherein the group:
- R1 is a 5-, 6-, 7-, 8-, 9-, or 10-membered aryl or heteroaryl, or a 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered cycloalkyl or heterocycloalkyl group, wherein the heteroaryl or heterocycloalkyl group can have from 1 to 3 heteroatoms independently selected from O, N or S, or a carbon atom in the cycloalkyl or heterocycloalkyl group can be part of a C═O group, and the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group is substituted with 0, 1, 2, 3, or 4 substituents independently selected from halo, —CN, —C1-6alkyl, haloC1-6alkyl, —OH, —O—C1-6alkyl, —O-haloC1-6alkyl, —C(═O)ORa, or —(CRbRb)nNRaRa;
- R2 is C1-6alkyl, or a 5-, 6-, 7-, 8-, 9-, or 10-membered aryl or heteroaryl, or a 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered cycloalkyl or heterocycloalkyl group, where the heteroaryl or heterocycloalkyl group can have from 1 to 3 heteroatoms independently selected from O, N or S, or a carbon atom in the cycloalkyl or heterocycloalkyl group can be part of a C═O group, and the alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl group is optionally substituted with from 1 to 5 R6 substituents independently selected from halo, —CN, —C1-6alkyl, haloC1-6alkyl, —OH, —O—C1-6alkyl, —O-haloC1-6alkyl, —(CRbRb)mA, —C2-6alkenyl-A, —C2-6alkynyl-A, or —O(CRbRb)m-A;
- each R3 is independently selected from H, —C1-6alkyl, haloC1-6alkyl, or halo;
- each R4 is independently selected from H, —C1-6alkyl, haloC1-6alkyl, or halo;
- each R5 is independently selected from H, —C1-6alkyl, haloC1-6alkyl, or halo;
- A is a 4 to 9 membered aryl, heteroaryl, or heterocycloalkyl group, or a 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered cycloalkyl group, where the heteroaryl or heterocycloalkyl group can have from 1 to 3 heteroatoms independently selected from O, N or S;
- and the aryl, heteroaryl, heterocycloalkyl, or cycloalkyl group is substituted with 0, 1, 2, 3, or 4 R7 substituents independently selected from halo, —NRaRa, —C1-6alkyl, —O—C1-6alkyl, —(CRbRb)mOH, hydroxyC1-6alkyl, haloC1-6alkyl, —O-haloC1-6alkyl, —CN, —C(═O)NRaRa, —O—(CRbRb)mB or —(CRbRb)mB;
- B is a 5 to 6 membered aryl, heteroaryl, or heterocycloalkyl group, or a 3 to 5 membered cycloalkyl group, where the heteroaryl or heterocycloalkyl group can have from 1 to 3 heteroatoms independently selected from O, N or S;
- and the aryl, heteroaryl, cycloalkyl or heterocycloalkyl group is substituted with 0, 1, 2, 3, or 4 R8 substituents independently selected from halo, —NRaRa, —C1-6alkyl, —OC1-6alkyl, hydroxyC1-6alkyl, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2, —OCH2F, —CN or —C(═O)NRaRa;
- each Ra is independently H, halo, —CN, —NRbRb, —OH, —C1-6alkyl, —C1-6haloalkyl, —OC1-6haloalkyl, or —OC1-6alkyl;
- each Rb is independently H, halo, —CN, —NRbRb, —OH, —C1-6alkyl, —C1-6haloalkyl, —OC1-6haloalkyl, or —OC1-6alkyl;
- each Rc is independently H or —C1-6alkyl;
- each n is independently 0, 1, 2, 3 or 4;
- and
- each m is independently 0, 1, 2, 3 or 4.
Dependencies are inferred from the claim text.